Summary

Eligibility
for people ages 50 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek to enroll approximately 20% of the study participants from under-represented minority populations (e.g., racial / ethnic minority groups, socioeconomically disadvantaged populations, rural populations).

Official Title

REACH Study: Galleri® in the Medicare Population.

Keywords

Cancer, ctDNA, Circulating tumor DNA, Screening, Cancer, Multi-Cancer Early Detection Test (Galleri®), (Galleri + UC), (UC) alone

Eligibility

You can join if…

Open to people ages 50 years and up

For Galleri + UC (Galleri-Tested Arm):

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Aged ≥50 years with Medicare coverage, including Traditional Medicare (Part A & B or Dual Eligibles) or Medicare Advantage.
  • Capable of giving informed consent that is legally effective (consent provided by a legally authorized representative is not permitted in this protocol).

For UC (Not Galleri-tested Arm):

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Aged ≥ 50 years with Medicare coverage, including Traditional Medicare (Part A & B or Dual Eligibles) or Medicare Advantage.
  • Have had ≥ 1 UC visit

You CAN'T join if...

For Galleri + UC (Galleri-Tested Arm):

  • Evidence of having had a previous MCED test (including but not limited to the Galleri test, e.g. CancerSeek, PanSeer). Participation in a study such as GRAIL's STRIVE study where results were not returned is not an exclusion criterion.
  • Undergoing clinical evaluation for suspicion of cancer within 6 months prior to enrollment. Personal history of hematologic malignancy and/or invasive solid tumor (excluding non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin):
    1. Diagnosed ≤3 years before expected enrollment date and/or
    2. Diagnosed >3 years before expected enrollment date and never treated and/or
    3. Currently undergoing active cancer management (not including adjuvant hormone therapy for breast or prostate cancer).
  • Current pregnancy.
  • Individuals who are currently inpatients at a participating site.
  • Individuals who are not willing or able to comply with the protocol procedures.
  • Individuals who are not currently registered patients at a participating center.
  • Previous or current employees or contractors of GRAIL.

For UC (Not Galleri-tested Arm):

  • Evidence of having had a previous MCED test (including but not limited to the Galleri test, eg.CancerSeek, PanSeer). Participation in a study such as GRAIL's STRIVE study where results were not returned is not an exclusion criterion.
  • Undergoing clinical evaluation for suspicion of cancer.
  • Personal history of hematologic malignancy and/or invasive solid tumor (not including non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin):
    1. Diagnosed ≤3 years before expected enrollment date and/or
    2. Diagnosed >3 years before expected enrollment date and never treated and/or
    3. Currently undergoing active cancer management (not including adjuvant hormone therapy for breast or prostate cancer).
  • Current pregnancy.
  • Individuals who are currently inpatients at a participating site.

Locations

  • UCSF Health System accepting new patients
    San Francisco California 94158 United States
  • Sutter Valley Hospitals PAMF Sutter accepting new patients
    Palo Alto California 94301 United States
  • Sutter Valley Hospitals Fairfield accepting new patients
    Vallejo California 94589 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
GRAIL, Inc.
ID
NCT05673018
Study Type
Interventional
Participants
Expecting 50000 study participants
Last Updated